Either you have JavaScript disabled or your browser does not support Javascript . To work properly, this page requires JavaScript to be enabled.
How to enable JavaScript in your browser?

Telacebec - Qurient Co

Drug Profile

Telacebec - Qurient Co

Alternative Names: Q-203

Latest Information Update: 07 Feb 2023

Price : $50 *
  • Adis is an information provider. We do not sell or distribute actual drugs.
  • Final gross price and currency may vary according to local VAT and billing address.
  • Your purchase entitles you to full access to the information contained in our drug profile at the time of purchase.
  • A link to download a PDF version of the drug profile will be included in your email receipt.

At a glance

  • Originator Qurient Co
  • Class Amides; Anti-inflammatories; Antibacterials; Antituberculars; Imidazoles; Piperidines; Pyridines; Small molecules
  • Mechanism of Action Bacterial growth inhibitors; Electron transport complex III inhibitors; Leukotriene inhibitors
  • Orphan Drug Status

    Orphan designation is assigned by a regulatory body to encourage companies to develop drugs for rare diseases.

    Yes - Tuberculosis
  • New Molecular Entity Yes

Highest Development Phases

  • Phase II COVID 2019 infections; SARS-CoV-2 acute respiratory disease; Tuberculosis
  • Phase I Buruli ulcer

Most Recent Events

  • 03 Feb 2023 Telacebec licensed to Global Alliance for TB Drug Development worldwide (except South Korea, Russia and Commonwealth of Independent States (CIS) countries) for the treatment of Tuberculosis
  • 07 Mar 2022 Phase-I clinical trials in Buruli-ulcer in South Korea (unspecified route) prior to March 2022 (Qurient pipeline, March 2022)
  • 12 Feb 2022 Qurient Co terminates a phase-II trial due to its own decision in COVID-2019 infections in South Africa (PO) (NCT04847583)
Subscriber content

You need to be a logged in subscriber to view this content.

If your organization has a subscription then there are several options available to help you access AdisInsight, even while working remotely.

  • IP authentication when working within your organization’s network.
  • with a username/password associated to your organization’s account.
  • Persisted access using your organization’s identifier stored in your user browser for 90 days.
  • Federated access using single sign-on credentials.
  • Contact us at AsktheExpert.AdisInsight@springer.com for assistance.

If your organization does not have a subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Buy a PDF version of the profile.
  • Request a free trial
Back to top